LEADS BIOLABS-B(09887): One LBL-034 clinical study has been selected to be the first oral presentation on the first day of the 67th ASH Annual Meeting.
Virtzbiotech-B (09887) announces that 5 research abstracts have been selected for presentation at the American Society of Hematology's 6th...
LEADS BIOLABS-B(09887) has announced that 5 research abstracts have been selected to be presented at the 67th annual meeting of the American Society of Hematology. The company is pleased to provide further details on its investigational new drugs LBL-034 and LBL-076, with multiple research abstracts on these drugs being included in the 67th ASH Annual Meeting. One clinical study on LBL-034 has been selected to be the first oral presentation on the opening day of the conference, showcasing the latest efficacy and safety data of LBL-034 in relapsed/refractory multiple myeloma patients.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
